表紙
市場調査レポート

糖尿病性神経障害:パイプライン分析

Diabetic Neuropathy - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 192558
出版日 ページ情報 英文 119 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.12円で換算しております。
Back to Top
糖尿病性神経障害:パイプライン分析 Diabetic Neuropathy - Pipeline Review, H1 2016
出版日: 2016年05月18日 ページ情報: 英文 119 Pages
概要

糖尿病性神経障害は、糖尿病でよく見られる合併症で、痛みなどを感じることができる神経の損傷です。うずき、しびれ、灼熱感、痛みなどの症状が見られます。素因として、肥満、高血圧、高脂質・高血糖、喫煙などが挙げられます。投薬治療や食習慣の改善で、管理することが可能です。

当レポートでは、糖尿病性神経障害に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

糖尿病性神経障害の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Achelios Therapeutics, Inc.
  • Araim Pharmaceuticals, Inc.
  • Celgene Corporation
  • Commence Bio, Inc.
  • Glenmark Pharmaceuticals Ltd.
  • Glucox Biotech AB
  • Kineta, Inc.
  • Lpath, Inc.
  • Neuralstem, Inc.
  • NovaLead Pharma Pvt. Ltd.
  • Omeros Corporation
  • PhiloGene, Inc.
  • Reata Pharmaceuticals, Inc.
  • Relief Therapeutics S.A.
  • Sucampo Pharmaceuticals, Inc.
  • 大日本住友製薬
  • ViroMed Co., Ltd.

治療薬の評価

  • 単独療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8033IDB

Summary

Global Markets Direct's, 'Diabetic Neuropathy - Pipeline Review, H1 2016', provides an overview of the Diabetic Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Diabetic Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Diabetic Neuropathy and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Diabetic Neuropathy
  • The report reviews pipeline therapeutics for Diabetic Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Diabetic Neuropathy therapeutics and enlists all their major and minor projects
  • The report assesses Diabetic Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Diabetic Neuropathy

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Diabetic Neuropathy
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Diabetic Neuropathy pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Diabetic Neuropathy Overview
  • Therapeutics Development
    • Pipeline Products for Diabetic Neuropathy - Overview
    • Pipeline Products for Diabetic Neuropathy - Comparative Analysis
  • Diabetic Neuropathy - Therapeutics under Development by Companies
  • Diabetic Neuropathy - Therapeutics under Investigation by Universities/Institutes
  • Diabetic Neuropathy - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Diabetic Neuropathy - Products under Development by Companies
  • Diabetic Neuropathy - Products under Investigation by Universities/Institutes
  • Diabetic Neuropathy - Companies Involved in Therapeutics Development
    • Achelios Therapeutics, Inc.
    • Araim Pharmaceuticals, Inc.
    • Celgene Corporation
    • Commence Bio, Inc.
    • Glenmark Pharmaceuticals Ltd.
    • Glucox Biotech AB
    • Kineta, Inc.
    • Lpath, Inc.
    • Neuralstem, Inc.
    • NovaLead Pharma Pvt. Ltd.
    • Omeros Corporation
    • PhiloGene, Inc.
    • Reata Pharmaceuticals, Inc.
    • Relief Therapeutics S.A.
    • Sucampo Pharmaceuticals, Inc.
    • Sumitomo Dainippon Pharma Co., Ltd.
    • ViroMed Co., Ltd.
  • Diabetic Neuropathy - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • atexakin alfa - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • benfotiamine - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BNV-222 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cibinetide - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CMB-200 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cyndacel-M - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Flexicaine Peel - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • GRC-17536 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ketoprofen - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Lpathomab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibodies to Inhibit MASP-2 for Rheumatoid Arthritis and Diabetic Complications - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ND-07 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NLP-198 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • NSI-566 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMS-721 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PDA-002 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Peptide to Activate G Protein-Coupled Receptor Mas for Cardiovascular, Metabolic Disorders and Erectile Dysfunction - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pirenzepine hydrochloride - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ranirestat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein to Antagonize VEGFR-2 for Oncology and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RTA-901 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • RTU-1096 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule for Pain - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecule to Inhibit NOX-4 for Diabetic Neuropathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Diabetic Neuropathy - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • U-2902 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VM-202 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Diabetic Neuropathy - Recent Pipeline Updates
  • Diabetic Neuropathy - Dormant Projects
  • Diabetic Neuropathy - Discontinued Products
  • Diabetic Neuropathy - Product Development Milestones
    • Featured News & Press Releases
      • Mar 06, 2015: ViroMed dba VM BioPharma: A Phase II Study Done at Northwestern Hospital Shows Potential Relief for Diabetics with Painful Condition
      • Sep 17, 2014: Glenmark's TRPA1 Antagonist 'GRC 17536' Shows Positive Data in a Proof of Concept Study
      • Sep 23, 2013: Lpath Awarded NIH SBIR Grant for Lpathomab
      • May 11, 2011: Dainippon Sumitomo Pharma Announces Results Of Phase II Clinical Trial For Ranirestat For Diabetic Complications
      • Mar 18, 2011: ViroMed Enrolls Final Patient For US VM202-DPN Phase I/II Clinical Trial
      • Mar 04, 2009: ViroMed Receives Approval from US FDA for Phase I/II Trial for Diabetic Neuropathy
      • Sep 29, 2005: Dainippon And Eisai Signs Licensing Agreement For A Potential New Treatment For Diabetic Neuropathy
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Diabetic Neuropathy, H1 2016
  • Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H1 2016
  • Diabetic Neuropathy - Pipeline by Achelios Therapeutics, Inc., H1 2016
  • Diabetic Neuropathy - Pipeline by Araim Pharmaceuticals, Inc., H1 2016
  • Diabetic Neuropathy - Pipeline by Celgene Corporation, H1 2016
  • Diabetic Neuropathy - Pipeline by Commence Bio, Inc., H1 2016
  • Diabetic Neuropathy - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016
  • Diabetic Neuropathy - Pipeline by Glucox Biotech AB, H1 2016
  • Diabetic Neuropathy - Pipeline by Kineta, Inc., H1 2016
  • Diabetic Neuropathy - Pipeline by Lpath, Inc., H1 2016
  • Diabetic Neuropathy - Pipeline by Neuralstem, Inc., H1 2016
  • Diabetic Neuropathy - Pipeline by NovaLead Pharma Pvt. Ltd., H1 2016
  • Diabetic Neuropathy - Pipeline by Omeros Corporation, H1 2016
  • Diabetic Neuropathy - Pipeline by PhiloGene, Inc., H1 2016
  • Diabetic Neuropathy - Pipeline by Reata Pharmaceuticals, Inc., H1 2016
  • Diabetic Neuropathy - Pipeline by Relief Therapeutics S.A., H1 2016
  • Diabetic Neuropathy - Pipeline by Sucampo Pharmaceuticals, Inc., H1 2016
  • Diabetic Neuropathy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016
  • Diabetic Neuropathy - Pipeline by ViroMed Co., Ltd., H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • Diabetic Neuropathy Therapeutics - Recent Pipeline Updates, H1 2016
  • Diabetic Neuropathy - Dormant Projects, H1 2016
  • Diabetic Neuropathy - Dormant Projects (Contd..1), H1 2016
  • Diabetic Neuropathy - Dormant Projects (Contd..2), H1 2016
  • Diabetic Neuropathy - Dormant Projects (Contd..3), H1 2016
  • Diabetic Neuropathy - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for Diabetic Neuropathy, H1 2016
  • Number of Products under Development for Diabetic Neuropathy - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Top 10 Targets, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Molecule Types, H1 2016
  • Number of Products by Stage and Molecule Types, H1 2016
Back to Top